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Abstract Information related to the clinical characteristics and isolated microbes associated with lung abscesses
comparing immunocompromised (IC) to non-immunocompromised (non-IC) patients is limited. A retrospective
review for1984^1996 identi¢ed 34 consecutive adultcases of lungabscess (representing 02% of all cases ofpneumonia),
including 10 non-IC and 24 IC patients. Comparison of age, gender, tobacco use, pre-existing pulmonary disease
or recognized aspiration risk factors were not signi¢cantly di¡erent between the two groups.Upper lobe involvement
accounted for the majority of cases, although multi-lobe involvement was limited to IC patients. There were no
di¡erences intheneed for surgical intervention, andmortalitywas verylow forboth groups.Anaerobeswere themost
frequent isolates for non-IC patients (30%), whereas aerobes were themost frequent isolate for IC patients (63%). Im-
portantly, certain organismswere exclusively isolated in the IC group andmultiple isolateswere obtained only fromthe
ICpatients.Thus, comparingnon-ICto ICpatients, clinical characteristicsmaybe similar whereas importantdi¡erences
may exist in the microbiology associated with lung abscess.These ¢ndings have important implications for the clinical
management of these patient groups, and support a strategy to aggressively identify microbial agents in abscess
material.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2001.1247, available online athttp://www.idealibrary.comon
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The clinical and microbiological characteristics of pa-
tients with lung abscess are well described (1,2). Most
cases are associatedwith recognized risk factors includ-
ing alcohol abuse, periodontal disease, seizure disorders,
oesophageal disorders and neurological bulbar dysfunc-
tion (3). Historically, lung abscesses are associated with
anaerobic bacteria (1).Recent reports suggest, however,
that the spectrum of aetiological agentsmay be evolving
(2), and that changes may in part re£ect an increased
number of immunosuppressed patients (2,4). Although
a number of reports suggest an expanded spectrum of
aetiological agents in immunosuppressed patients (3^7),
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pressedpatients has not been fully examined.
Recognizing the altered immune function and spec-
trum of lung infections in patients with chronic corticos-
teroid use (8^10), haematological or solid malignancies
(11,12), organ transplantation (12,13) and human immuno-
de¢ciency virus (HIV) infection (14^16), the clinical char-
acteristics and microbiology of lung abscess may be
di¡erentwhen compared to patients without underlying
immunosuppression.One report suggest fewer anaero-
bic isolates in immunocompromised patients (2). A
recent report of HIV-infected patients noted that
abscesses occurred in advanced HIV-related disease,
was associated with a broad spectrum of pathogens,
responded poorly to antibiotics and was associated
with a poor prognosis (4). Furthermore, the immune
dysfunction associated with conditions such as
diabetes mellitus (17,18) may predispose to certain pul-
monary infections (19), although the impact of diabetes
mellitus on lung abscess has not been fully investigated
(20^22).
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tations and microbiological isolates of lung abscesses
may have signi¢cant implications for guiding clinical diag-
nostic evaluations and empirical antimicrobial manage-
ment, especially in the immunocompromised host.
However, the clinical characteristics and aetiology of
lung abscess in immunocompromised hosts is not well
characterized, and studies comparing immunocompro-
mised to non-immunocompromisedpatients are limited.
The purpose of this study was to examine the clinical
characteristics andmicrobiology in cases of lung abscess
at a tertiary care urban medical center, comparing
immunocompromised to non-immunocompromised
patients.
METHODS
Setting
The Beth Israel Deaconess Medical Center, West
Campus, is a 375-bed tertiary care referral hospital
with general medical service, including infectious
disease and HIV clinical services, medical oncology and
hematology service, diabetic service, and pulmonary
and critical care services. Surgical services included gen-
eral surgical, thoracic surgical and solid organ transplant
service.
Identi¢cation of cases of lung abscess
Consecutive cases of lung abscess were identi¢ed
by a systematic search of all medical discharge summa-
ries with the appropriate International Classi¢cation
of Diseases-9 (ICD-9) discharge diagnosis, review of
radiological reports and surgical/anatomical pathology
reports identifying the diagnosis of lung abscess for
the period 1984^996. Only cases of lung abscess in
patients with clinical and radiographical evidence
(conventional chest radiograph, thoracic CT scan)
(23,24), or surgically obtained specimens were included
in the study. Lung abscess was de¢ned as a cavity
X2 cm in diameter.Patientswith lung abscess secondary
to recent (o30 days) thoracic surgery, or patients with
cavitating, necrotic lung neoplasms were not included in
this study.
A retrospective review of medical records of all iden-
ti¢ed cases was performed, and all clinical data were re-
cordedon a standardized form,withparticular attention
to patient age, gender, ethnicity, underlyingmedical con-
ditions (including seizure disorder, CVA or neuromuscu-
lar disease), previous pulmonary infections, recognized
aspiration risks, alcohol and tobacco use. For the pa-
tients infected with HIV, additional information included
the most recent peripheral blood CD4+ T-lymphocyte
counts and use of antimicrobial chemoprophylaxis. For
each identi¢edcase, informationwas recorded for symp-toms at time of presentation, prior antimicrobial use,
radiographic localization of abscess, mode of diagnoses
of lung abscess, microbiological agent identi¢ed from ab-
scess material, cultures of respiratory tract specimens
or blood, requirement for surgical intervention, duration
of hospitalization andmortality.
For the purpose of the study patients were divided
into two groups: (1) non-immunocompromised group,
which included patients with no clinically recognized un-
derlyingmedical conditions associatedwith immunosup-
pression; and (2) immunocompromised group, which
includedpatientswith clinicallyrecognized immunocom-
promised conditions, includinghuman immunode¢ciency
virus type-1 (HIV-1) infection, organ transplant recipi-
ents, persons requiring chronic corticosteroids (de¢ned
as the equivalent of prednisone X20mg daily for X2
months) or other immunosuppressive agents for in£am-
matory conditions, persons with underlying hematologi-
cal or solid malignancy, and persons with diabetes
mellitus.
Statistical analysis
Statistical analysis of non-continuous dichotomous data
were compared by the Chi-square test (withYates cor-
rection) or the Fischer’s exact test as appropriate using
INSTAT2 statistical package (Graphpad Software; San
Diego, CA, U.S.A.) on an IBM PS/2 120 MB computer
(IBM Corp; Armonk, NY, U.S.A.). All P-values were
two-sided and statistical signi¢cance was accepted for
Po005.
RESULTS
Clinical characteristics
A total of 46 cases of lung abscess were identi¢ed, and
medical records for all 46 cases were reviewed. Twelve
cases were excluded because the identi¢ed abscess re-
presented lung necrosis complicating post-obstructive
pneumonia, cavitating lung neoplasm, or the available
medical records were incomplete. A total of 34 cases
were included in this study, which represented a 02%
incidence of lung abscess for all hospitalized cases of
pneumonia.The clinical characteristics for the 10 indivi-
duals in thenon-immunocompromisedgroup and 24 indi-
viduals in the immunocompromised group are presented
inTable 1. For the immunocompromised group, all HIV+
individuals and the organ transplantreciptientwere con-
¢rmed HIV sero-negative. Although speci¢c serum HIV
antibody data were not available for the non-immuno-
compromised subjects, none had recognized HIV risk
factors, all hadnormalperipheralwhiteblood cell counts
and none had lymphopenia.
Comparison of age, gender, tobacco use, pre-existing
pulmonary disease or recognized aspiration risk factors
TABLE 1. Clinical characteristics of patientswith lungabscess
Non-immunocompromised Immunocompromised P-value
Total cases (n) 10 24
Age, yrs (mean7SD) 591717 501718 NS
Gender
Male (n) 7 20 NS
Female (n) 3 4 NS
Ethnicity
Caucasian 8 18
Black F 2
Hispanic F 3
Asian F 1
Unavailable 2 F
Immunocompromised condition
HIVdisease (n) F 7
Malignancy (n) F 7
Diabetesmellitus (n) F 5
Chronic corticosteroiduse (n) F 4
Liver transplant recipient (n) F 1
Tobacco use, n (%) 7 (70%) 16 (67%) NS
Pre-existingpulmonarydisease*, n (%) 3 (30%) 6 (25%) NS
Identi¢ed aspirationriskw, n (%) 5 (50%) 11 (46%) NS
Antibiotics during the1monthprior to diagnosis 10 (100%) 24 (100%) NS
*COPD, asthma orbronchiectasis.
wEthanoluse, seizure disorder, peridontal disease, bulbarneurological oroesophogeal disease.
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the two groups. For the non-immunocompromised
group, 20% of patients had prior remote bacterial pneu-
monia compared to 54% for the immunocompromised
group (P4005). All subjectswereprescribed antimicro-
bials at the time of diagnosis of lung abscess. All subjects
had used antimicrobials within 3 months of the diagnosis
of lung abscess, and included cephalosporins (n=13),
macrolides (n=10), semisynthetic penicillins (n=7) and
combination penicillin/sulbactam (n=4). There were no
di¡erences in the use of speci¢c antimicrobials compar-
ing non-immunocompromised to non-immunocompro-
mised subjects.
For the immunocompromised group, in addition to
the ¢ve patients with diabetesmellitus, diabetesmellitus
was a co-existingmedical condition in two individuals re-
quiring chronic corticosteroids, and in each of one pa-
tient with HIV infection, haematological malignancy and
liver transplant recipient. For the HIV-infected patients,
allwere con¢rmedHIV+, and themean peripheral blood
CD4+ T-lymphocyte count was 662756 cellsmm3
(range 20^157 cellsmm3), 4/7 were prescribed anti-
P. carinii prophylaxis (two oral trimethoprim-sulfa-
methoxozole, two aerosolized pentamadine), and 4/7
hadprior opportunistic infections.None of the other im-
munocompromised patients had prior opportunistic in-
fections. Only patients in the immunocompromisedgroup were prescribed prophylactic antimicrobials (as
noted above) prior to the diagnosis of lung abscess.
Clinical signs and symptoms of lung abscess
Clinical signs and symptoms at the time of presentation
areprovided inTable 2.Therewere no statistically signi¢-
cant di¡erences comparing non-immunocompromised
to immunocompromised patients. For the non-immuno-
compromised patients, pleuritic chest pain (40%) was
themost common symptom atpresentation.For the im-
munocompromised patients, fever (46%) was the most
common symptom. A larger proportion of non-immuno-
compromised patients were asymptomatic (30%) at the
time of presentation, compared to immunocompro-
misedpatients (4%), although this di¡erencewas not sta-
tistically signi¢cant. Gastrointestinal symptoms
(diarrhoea, nausea and vomiting) were only reported in
the immunocompromised group (0% vs. 29%, P=007).
Radiographic localization of lung abscesses
The radiographic localization of lung abscesses is pre-
sented inTable 3. For each lobar distribution, therewere
no statistically signi¢cant di¡erences in the radiographic
localization of the lung abscess comparing the non-
TABLE 2. Symptoms and signs attime of presentation for patientswith lungabscess
Non-immunocompromised
(%)
Immunocompromised
(%)
P-value
Fever 20 46 NS
Cough 20 42 NS
Gastrointestinal symptoms* 0 29 007
Dyspnoea 20 21 NS
Weight loss 10 21 NS
Pleuritic chest pain 40 12 NS
Haemoptysis 10 8 NS
Asymptomatic 30 4 NS
TotalWBC105 (cellsmm3) 12074 12778 NS
*Nausea, vomitting, diarrhoea.
WBC=white blood cell count.
TABLE 3. Radiographic location of lungabscesses at presentation
Non-immunocompromised Immunocompromised P-value
RUL, n (%) 5 (50%) 8 (33%) NS
LUL, n (%) 2 (20) 5 (21) NS
LLL, n (%) 1 (10) 3 (12) NS
RLL, n (%) 0 3 (12) NS
Multiple lobes, n (%) 0 3 (12) NS
RML, n (%) 2 (20) 2 (8%) NS
Total 10 (100%) 24 (100%)
RUL: rightupper lobe;LUL: left upper lobe;LLL: left lower lobe;RLL: right lower lobe;RML: rightmiddle lobe.
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mised group.Collectively, the upper lobes accounted for
the majority of cases, with 70% of non-immunocompro-
mised patients and 54% of immunocompromised pa-
tients (P4005). For both groups, the right upper lobe
(RUL) was more often involved than the left upper lobe
(LUL), although this di¡erencewas not statistically signif-
icant. Multiple lung abscesses (Xtwo sites) were ob-
served only in the immunocompromised group,
occurring in12% of cases.
Diagnostic approach to determinemicrobial
aetiological agent
All patients had at least one diagnostic procedure in an
attempt to identify a pathogen (Table 4). A surgical speci-
menmost often providedmaterialwhich identi¢ed a po-
tential pathogen for each group. Bronchoscopic
specimens, including site directed bronchoalveolar la-
vage (BAL) or trans-bronchial lung biopsy, identi¢ed a
pathogen in six cases, including one non-immunocom-
promisedpatient and ¢ve immunocompromisedpatients
(one included transbronchial biopsies). Quantitative cul-tureswere not performed on BAL specimens.For indivi-
dualswith positiveblood cultures, the samemicrobewas
isolated from theblood andrespiratory tract specimens.
Only two patients (59%), both immunocompromised,
allowed only examination of sputum specimens and re-
fused more invasive investigation. For six individuals, no
potential pathogen was isolated despite sputum and
blood cultures, bronchoscopy, CT-guided needle biopsy
or surgical biopsy. All specimenswere submitted for rou-
tine gram stain, routine bacterial culture, Legionella spp.
culture, fungal culture, acid fast bacillus (AFB) stain and
culture, and P. carinii stain. Anaerobic culture were per-
formed on490% of the submitted specimens.
Microbial isolates associatedwith
lung abscesses
Identifying the most de¢nitive diagnostic procedure for
each case, the microbes isolated from the patients with
lung abscesses are presented inTable 5.Compared to the
non-immunocompromised group, a trend towards a sig-
ni¢cantly larger proportion of cases with isolated aero-
bic bacteria was observed for the immunocompromised
TABLE 4. Diagnosticmethod* which identi¢ed a potentialpathogen inpatientswith lungabscess
Non-immunocompromised Immunocompromised Total
Surgicalmaterial, n (%) 4 8 12 (35)
Bronchoscopy, n (%) 1 5 6 (18)
BAL (n) 1w 4
Transbronchial biopsy (n) 0 1
CT-guidedneedle aspiration (n) (%) 1 4 5 (15)
Blood cultures, n (%) 1z 2z 3 (88)
Sputumculture, n (%) 0 2} 2 (59)
No agent identi¢ed, n (%) 3 3 6 (18)
*Re£ectthemethodsutilized to base clinical decisions regardingantimicrobial therapy.
wBronchoscopic ¢nding supportedby serumimmunoglobulin levels.
zSame organismsisolated fromblood cultures andrespiratory tract specimens.
}Both patients refused any further invasive investigations.
TABLE 5. Microbial isolates associatedwith lungabscesses*
Non-immunocompromised Immunocompromised
Aerobic bactera, n (%) 2 (20) 15 (63)w
S. aureus 1 5
P. aerugenosa F 3
Hemophilus spp. (non-in£uenza) F 2
P. maltiphilia 0 1
H. in£uenza F 1
b-Streptococcus 1 1
Enterobacter spp. F 1
K. oxytoca F 1
Anaerobic bacteria, n (%) 3 (30) 2 (8)
Actinomyces spp. 1 2
P. acnes 1 F
Peptostreptococcus spp. 1 F
Atypical bacteria, n (%) 0 (0) 2 (8)
Legionella spp. (non-pneumonphila) F 2
Mycobacterium, n (%) F 1 (4)
M. avium complex F 1
Fungi, n (%) 2 (20) 5 (21)
Aspergillus spp. 2 4
Candida spp. F 1
No organismidenti¢ed, n (%) 3 (30) 3 (8)
*Some abscess specimens yieldedmultiple organisms.
wP=0057.
182 RESPIRATORYMEDICINEgroup (20% vs. 63%;P=0057), whereas no signi¢cant dif-
ferences were observed for the isolation of anaerobic,
Legionella spp.,mycobacteria or fungi.For thenon-immu-
nocompromisedgroup, anaerobesweremost frequently
isolated, followed equally by aerobic bacteria and fungi.
For the immunocompromised patients, aerobic bacteria
were most commonly isolated, representing a broad
spectrum with P. aerugenosa, Hemophilis spp. (non-in£u-
enza), X. maltophilia, H. in£uenza, Enterobacter spp. and
K. oxytoca exclusively isolated in the immunocompro-misedgroup.Othermicro-organisms exclusively isolated
in specimens from immunocompromised patients in-
cluded non-pneumophilia Legionella spp., M. avium com-
plex and Candida spp.The patient with Candida spp. had
yeast isolated from surgical specimens of multiple pul-
monary abscesses and high-grade fungaemia.
Multiple isolates (Xtwo micro-organisms) were ob-
tained in seven cases, all in immunocompromised pa-
tients.Whereas anaerobes were isolated in 20% of cases
for non-immunocompromised patients, no anaerobes
TABLE 6. Clinicalmanagement and outcomes of patientswith lungabscess
Non-immunocompromised Immunocompromised
Medicalmanagementonly, n (%) 5 (50) 15 (63)
Surgicalmanagement, n (%) 5 (50) 9 (37)
Discharged, n (%) 10 (100) 22 (92)
Hospitalmortality, n (%) 0 (0) 2 (8)
LUNGABSCESS INADULTS 183were isolated for the immunocompromised group,
although this did not achieve statistical signi¢cance.
There were no cases with Mycobacterium tuberculosis
identi¢ed in either group. Although a larger proportion
of non-immunocompromised cases failed to identify a
potential pathogen (30% vs. 8%), this did not achieve sta-
tistical signi¢cance.
Recognizing the limitations of isolatingmicrobes from
specimens of sputum and BAL as the aetiology of lung
infections, the current study revealed the following: (1)
for the non-immunocompromised group, only one pa-
tient had BAL as the most de¢nitive diagnostic proce-
dure.The BAL specimen yielded Aspergillus spp. and this
patient also had positive serology for Aspergillus antigen;
(2) for the immunocompromisedgroup, the twopatients
who had only sputum specimens as the most de¢nitive
diagnostic procedure, one yielded Klebsiella oxytoca and
Hemophilus spp. (non-in£uenza), and one yielded Actino-
myces and Hemophilus spp. (non-in£uenza). For the ¢ve
patients with BAL as themost de¢nitive diagnostic pro-
cedure, the isolated organisms included E. coli (co-iso-
lated from three specimens), X. maltophilia, S. aureus
and Enterobacter spp. For both groups, all sputum and
BAL specimens also co-isolated C. albicans, but none of
the isolates were considered pathogenic unless C. albi-
cans was also identi¢ed in blood cultures, or specimens
from surgicalmaterial or CT-guided needle aspiration.
Overall, for the non-immunocompromised patients, a
potential pathogenwas identi¢ed in 70% of all cases. For
the immunocompromised patients, potential microbial
diagnoses were identi¢ed in 88% of all cases. Excluding
sputumcultures, andrecognizing thepossible limitations
of BAL specimens (even in immunocompromised pa-
tients), the yield was 63^79% (excluding or including
BAL results, respectively).
Clinicalmanagement and outcomes
Allpatientswereprescribed antimicrobial agents, includ-
ing speci¢c agents with activity directed against isolated
microorganisms, for a period of 4^6weeks.For thenon-
immunocompromised group, medical management
alonewas employed for 50%. All cases receiving surgical
treatment represented patients speci¢cally referred to
the Beth Israel Deconess Medical Center (BIDMC) forsurgical evaluation, and indications included concern for
possible cavitating malignancy (n=3) and haemoptysis
(n=2).Overall for the group, all patientswere discharged
from the hospital.
For the immunocompromised group, medical man-
agement alone was employed for 63%. For patients re-
ceiving surgical treatment, most were initially referred
to the BIDMC surgical service, and indications included
progressive abscess enlargement despite antimicrobial
treatment (n=4), suspicion for cavitating malignancy
(n=2), haemoptysis (n=2) andpneumothorax (n=1).Over-
all mortality during the hospitalization was 8% (one pa-
tient with Aspergillus abscess and one patient with C.
albicans abscess died) and the remaining 92% of patients
were discharged.
Three-month follow up data were available for 17
(50%) patients.For the four in the non-immunocompro-
mised group, two had complete resolution of the ab-
scess, whereas for two other cases there was no
resolution (one of these two required thoracoplasty for
haemopytsis). For the13 immunocompromised patients,
12 had complete resolution of the abscess and one pa-
tientwas admittedwith a newcavity in the opposite lung
at 3 months.
DISCUSSION
This retrospective review of consecutive cases of lung
abscess in adults at tertiary caremedical center suggests
that certain important clinical similarities as well as im-
portant clinical di¡erences exist comparing immuno-
compromised patients to patients without recognized
immunocompromised states. For both non-immuno-
compromised and immunocompromised patients, the
identi¢ed cases were predominantly male patients
(70^83%), with a mean age of 50^59 years, with a his-
tory of tobacco use (67^70%) and with underlying pul-
monary disease (25^30%). Recognized aspiration risks
were identi¢ed equally in both groups, present in 46^
50% of cases.
Several important clinical di¡erences were suggested
in this study.The observation that twice asmany cases of
lung abscesswere identi¢ed in the immunocompromised
group compared to the non-immunocompromised
group suggests that primary lung abscess may be more
184 RESPIRATORYMEDICINEcommon in immunocompromised hosts, although data
to allow independent incidence determination for each
group was not available. Whereas most non-immuno-
compromised patients were asymptomatic or experi-
enced pleuritic chest pain at the time of presentation,
most immunocompromised patients experienced fever
and cough, although these di¡erences did not achieve
statistical signi¢cance when the two groups were com-
pared. Gastrointestinal symptoms were exclusively ob-
served in the immunocompromised group.
Theradiographical localization of lung abscess demon-
strated that both non-immunocompromised and immu-
nocompromised groups had predominantly upper lobe
involvement (70% vs. 54%, respectively), similar to other
reports (2,4,25). Although lower lobe involvement was
observed more frequently with immunocompromised
patients (24% vs.10%), this di¡erence did not achieve sta-
tistical signi¢cance. Multiple-lobe involvement was iden-
ti¢ed only in immunocompromised patients.
A potential aetiological agentwas identi¢ed in thema-
jority of cases for both non-immunocompromised (70%)
and immunocompromised (63^88%) patients. For the
non-immunocompromised group aerobic bacteria (30%)
were most frequently isolated microbes, followed
equallyby anaerobic bacteria (20%) and fungi (20%). Simi-
larly, for the immunocompromisedgroup aerobicbacter-
ia (71%) were the most frequent isolates, followed by
fungi (21%), ¢ndings similar to immunocompromised pa-
tients in other reports (2,4). Importantly, immunocom-
promised patients did not have anaerobic isolates, were
more likely to havemultiple pathogens isolated from ab-
scessmaterial, and exhibited a broad spectrum of poten-
tial pathogens such as P. aerugenosa,Hemophilis spp. (non-
in£uenza), X. maltophilia, H. in£uenza, Enterobacter spp.,
K. oxytoca, non-pnuemophilia Legionella spp., M. avium
complex and Candida spp., which were exclusively iso-
lated in the immunocompromised group.
We observed a high rate of recovery of microbial iso-
lates from clinical specimens, where potential pathogens
were identi¢ed in 824% of all cases included in the study.
The high rate of recoverymay in part re£ect the aggres-
sive approach to identify potential pathogens at our insti-
tution. For the bronchoscopic specimens, although
quantitative cultures were not performed, isolation of
potential pathogens from the airways of immunocom-
promised individuals often are considered pathogenic
(26). Recognizing that microbes isolated from sputum
specimens may not re£ect true pathogens, exclusion of
these cases yielded an overall rate of 765% isolation of
potential pathogens. Although the isolated microbes
may represent colonization rather than true infection,
the observation that individuals clinically responded to
speci¢c antimicrobial therapy directed against the iso-
lated organisms in part supports a causative role. Finally,
we observed a broad spectrum of isolated microbes,
especially from the immunocompromised group, manyisolateswhichwouldnotrespond tomost empirical anti-
microbial regimens (27).These observations suggest the
importance of identifying a potential causative agent,
and support a strategy to aggressively identify aetiologi-
cal agents from abscessmaterial.
The lowrate of recoveryof anaerobes for bothgroups
in the current study contrasts the ¢ndings of prior re-
ports (1,28,29) where anaerobes were isolated in up to
93% of cases (exclusively in 56% of cases). As 490% of
specimens in the current study were submitted for anae-
robic culture, the low incidence of anaerobic isolation in
the current study does not re£ect omission of anaerobic
cultures, but may re£ect sampling methods (no trans-
tracheal aspirations were performed in the current
study), lapses in appropriatehandlingofrespiratory tract
specimens, or changes in themicrobiological spectrumin
our study populations, perhaps re£ecting the state of
immunocompetence. Alternatively, the spectrum of mi-
crobesmay be altered due to the high rate of premorbid
antibiotic prescriptions for both groups. Importantly, a
recent report of lung abscess in HIV-infected individuals
failed to identify anaerobes (4), which taken together
with the ¢ndings in the current study suggests that the
microbial aetiology for immunocompromised patients
maybedistinctfromnon-immunocompromisedpatients.
The observed mortality associated with lung abscess
was low for both groups, and lower than the reported
mortality rates of 15^28% (2,30^32). The favourable
outcomes in the current study may in part re£ect the
patientpopulation, the aggressivemanagement (employ-
ing surgical resection inmany cases), and the use of anti-
microbial agents directed against all isolated microbial
agents.The only observed deaths occurred in the immu-
nocompromisedpatients, andboth cases involved fungal
abscess. Although de¢nitive conclusions are notpossible,
other investigators have reported high mortality rates
associatedwith fungal lung abscess (25,33).
Other limitations of this study include the retrospec-
tive nature and the relatively small number of cases iden-
ti¢ed in each group. The limited number of cases
identi¢ed despite a comprehensive review of medical re-
cords over a 13-year period suggests that the develop-
ment of lung abscessmay be infrequent, andmay re£ect
a change in the evolution of lung abscess, or may re£ect
antimicrobial use patterns, clinical practices or patient
populations speci¢c to our institution. The absence of
statistical di¡erences comparing the two groupsmay re-
£ect the fact that di¡erences do not exist, or perhaps
the small number the non-immunocompromised pa-
tients likely limited the statistical analysis comparing
these groups. The relatively limited number of each of
the immunocompromised patients did not allow for sub-
group analysis, such as determining the in£uence of dia-
betes mellitus. The inclusion of only cases requiring
hospitalization may under-estimate the total number of
actual cases of lung abscess at our institution, as ambula-
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dardized approach to the diagnostic and therapeutic
management of patients included in this retrospective
study, conclusions or recommendations regarding the
appropriate management practice is not possible.
Although a broad spectrum of immunocompromised
states were represented, including HIV disease, malig-
nancy, diabetes mellitus, chronic corticosteroid use, and
organ transplantion, the ¢ndingsmay not apply to other
immunocomromised patients. Finally, the experience at
our institution may not re£ect the experience of other
medical centers, although a broad spectrum of medical
conditions were represented in this study.
In summary, this retrospective review of lung ab-
scesses comparing non-immunocompromised patients
to immunocompromised patients notes that the clinical
characteristics of lung abscess are remarkably similar
comparing the two groups, with a favourable short-term
prognosis. However, several observations suggest that
important di¡erences may exist, as immunocompro-
misedpatientswith lung abscessmaypresentmore often
with gastrointestinal symptoms, more often have multi-
ple abscesses, more often have aerobic bacteria isolated
fromabscessmaterial, andmayhave exclusive isolation of
certain microbes or multiple microbes, although addi-
tional larger studies are needed to further assess for
these di¡erences. The observed broad spectrum of mi-
crobial isolates associated with lung abscesses for each
group has important implications for the clinical and em-
pirical management of these patients, and supports a
strategy to aggressively identify causative agents
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